Caregen Co.Ltd (214370) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Caregen Co.Ltd KRW 5,414, price KRW 42,550, upside -87.3%, quality 71 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands.
Show more
Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600 names. The company's products are used in anti-aging, anti-pigmentation, anti-hair loss, anti-inflammation, and other skin troubles, as well as blood sugar control, baby skin care, and acute muscle pain applications. In addition, its products in pipeline include pharmaceuticals in the areas of wet and dry macular degeneration, diabetic retinopathy, cataract, hyperhidrosis, pain relief, obesity, psoriasis, scar, arthritis, rhinitis, anti-virus, and Covid-19 treatment; and medical devices for face beauty treatment, scalp and hair improvement, body care, arthritis, and new face beauty treatment. Further, the company is developing cosmeceutical produts for anti-wrinkle, whitening, sun block, atopic dermatitis care, particulate matter inhibition, double chin removal, dark circle care, reduction of cellulite, sebum secretion control, and pore tightening applications; and food supplements in the areas of hangover cure, cholesterol control, and body fat lipolysis. Caregen Co., Ltd. was founded in 2001 and is based in Anyang-si, South Korea.
Stock analysis
Caregen Co.Ltd (214370) currently trades at 42,550 KRW, while our model-based Fair Value estimate is 5,414 KRW, 87.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 7,396 KRW per share, and 0 of the 25 models we run sit above the 42,550 KRW price.
Bear case: the Earnings-Based group reads lowest at 2,414 KRW, and 25 of the 25 models stay below the price. Evidence for this calculation is low.
Scenario range: 3,672 KRW (bear) to 7,690 KRW (bull), the price of 42,550 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Caregen Co.Ltd reported revenue of 72.8B KRW in FY2025 versus 59.1B KRW in FY2021, a compound +5.4%/yr. Reported net income was 20.1B KRW in FY2025, compounding −5.6%/yr from FY2021.
Key figures
Market cap 2.1T KRW (≈ $1.5B) · P/S ratio 31.4 · Dividend yield 2.1% · Net margin 27.6% · Return on equity 1,456% · Return on assets (EBIT) 13.3% · Operating margin 46.3% · Revenue (TTM) 65.0B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 72% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at −87%, 214370 screens richer than that median.
Fair Value models
Bear 3,672 KRWFair Value 5,414 KRWBull 7,690 KRW
Price 42,550 KRW · Upside -87.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.70/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−11.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.8%
Start year 2020 (pandemic). Over 10 years: +7.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−30.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−32.0%
Dividend (yield on the price)2.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−32.0% vs −15.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.53% → 28%
Start year 2020 (pandemic)
⚠ Revenue per share shrinking 15.0%/yr over ~7Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+51.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +48.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 52 stocks
Beats the industry median on 8/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score71 · Top 25%
Fair Value upside−87.3% · Bottom 25%
Profitability
Return on assets8.5% · Top 25%
Net margin (TTM)39.6% · Top 25%
Operating margin (TTM)46.3% · Top 25%
Growth and dividend
Revenue growth34.2% · Top 25%
Dividend yield (TTM)2.1% · Above median
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
P/S (TTM)0.02× · Cheapest 25%
P/FCF0.1× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 26
FUTURE (revenue growth)100· sector 51
PAST (return on equity)0· sector 15
HEALTH (low debt)0· sector 98
DIVIDEND (yield)41· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Caregen Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/214370
Frequently asked questions
Is Caregen Co.Ltd (214370) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of 5,414 KRW versus a price of 42,550 KRW, about −87% upside (overvalued).
What is the fair value of 214370?
Our model-based fair value for Caregen Co.Ltd is 5,414 KRW (as of Oct 1, 2026), built from audited fundamentals. The current price: 42,550 KRW.
What is the quality score of 214370?
Caregen Co.Ltd has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Caregen Co.Ltd (214370)?
Our model-based price target is the fair value of 5,414 KRW (as of Oct 1, 2026) from 25 valuation models. Cautious scenario 3,672 KRW, optimistic scenario 7,690 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Caregen Co.Ltd stock forecast for 2026?
Our models put fair value at 5,414 KRW, about −87% upside versus a price of 42,550 KRW (overvalued). Cautious scenario 3,672 KRW, optimistic scenario 7,690 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Caregen Co.Ltd (214370)?
Caregen Co.Ltd reported trailing-twelve-month revenue of about 65.0B KRW (latest available figure, as of Oct 1, 2026).
Does Caregen Co.Ltd pay a dividend?
Caregen Co.Ltd currently shows a dividend yield of about 2.05% relative to its recent price (as of Oct 1, 2026).
What growth is priced into Caregen Co.Ltd (214370)?
For today's price to be fair in a discounted-cash-flow model, Caregen Co.Ltd would have to grow free cash flow by +51.2 % per year for five years (discount rate 10.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.8 % per year. As of Oct 1, 2026.
What discount rate (WACC) does the fair value of 214370 use?
Our models discount Caregen Co.Ltd at 10.2 %: a base by market capitalisation (small), damped by beta 0.18, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Caregen Co.Ltd that is +51.2 % per year a year over ten years, using the same discount rate (10.2 %) and the same formula as our fair value.
How much growth has Caregen Co.Ltd (214370) delivered so far?
Over the past 5 years revenue at Caregen Co.Ltd grew +3.8 % a year. The price currently implies +51.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Caregen Co.Ltd (214370) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Caregen Co.Ltd (+51.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Caregen Co.Ltd (214370)?
The free-cash-flow yield on the price is 0.66 %: that much free cash flow Caregen Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Caregen Co.Ltd (214370)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Caregen Co.Ltd it is 5,414 KRW per share (as of Oct 1, 2026), against a price of 42,550 KRW. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Caregen Co.Ltd stock overvalued or undervalued in 2026?
As of Oct 1, 2026, 214370 trades above its calculated fair value: price 42,550 KRW, fair value 5,414 KRW, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 214370?
No. The price is what the market pays today (42,550 KRW); the fair value is what the company's own numbers justify (5,414 KRW). For Caregen Co.Ltd the two are 37,136 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Caregen Co.Ltd worth?
The market values Caregen Co.Ltd at about 2.1T KRW (market capitalisation, as of Oct 1, 2026). Per share that is 42,550 KRW; our models calculate a fair value of 5,414 KRW per share.
What do the bullish and bearish scenarios say about 214370?
Our models span a range for Caregen Co.Ltd: cautious scenario 3,672 KRW, base 5,414 KRW, optimistic 7,690 KRW per share (as of Oct 1, 2026, price 42,550 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 214370 from its 52-week high?
Caregen Co.Ltd trades at 42,550 KRW, about 72% below its 52-week high of 149,635 KRW and 8% above the low of 39,350 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 5,414 KRW is for.
Which stocks are comparable to Caregen Co.Ltd?
From the same area (Healthcare) we also value ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, SHUKRAPHAR, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Caregen Co.Ltd stock attractive at the current price?
The data as of Oct 1, 2026: price 42,550 KRW, calculated fair value 5,414 KRW (−87%), Quality Score 71/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 214370 calculated?
We run Caregen Co.Ltd through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 5,414 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Caregen Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Caregen Co.Ltd (214370)?
The closing price on Oct 2, 2026 was 42,550 KRW. Our model-based fair value is 5,414 KRW, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Caregen Co.Ltd right now?
A high-quality business (quality 71/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (7,690 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (3,672 KRW to 7,690 KRW) leaves room in how you read the outcome.
Key figures of Caregen Co.Ltd
How large is the market capitalisation of Caregen Co.Ltd (214370)?
The market capitalisation of Caregen Co.Ltd is 2.1T KRW (≈ $1.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Caregen Co.Ltd (214370)?
The price-to-sales ratio of Caregen Co.Ltd is 31.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Caregen Co.Ltd (214370)?
The dividend yield of Caregen Co.Ltd is 2.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Caregen Co.Ltd (214370)?
The net margin of Caregen Co.Ltd is 27.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Caregen Co.Ltd (214370)?
The return on equity (ROE) of Caregen Co.Ltd is 1,456% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Caregen Co.Ltd (214370)?
On an EBIT basis the return on assets of Caregen Co.Ltd is 13.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Caregen Co.Ltd (214370)?
The operating margin of Caregen Co.Ltd is 46.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Caregen Co.Ltd (214370)?
Revenue at Caregen Co.Ltd is growing +34.2% versus a year earlier (3y avg +1.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Caregen Co.Ltd (214370)?
Earnings per share at Caregen Co.Ltd are growing −4.4% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Caregen Co.Ltd in the live analysis
One click puts Caregen Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
